Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CD74 | P04233 | 1/20 | 0.62 |
| ▸ | MIF | P14174 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149119 | 0.88 | MIF (0.62) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL14559257 | 0.85 | RAB9A (0.64) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL16141200 | 0.84 | KMT2A (0.63) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL27981699 | 0.83 | KMT2A (0.62) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL10181870 | 0.83 | MAPT (0.75) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL2149143 | 0.82 | CD74 (0.62) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL16141179 | 0.82 | ALDH1A1 (0.64) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL3026762 | 0.82 | KMO (0.67) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL2149526 | 0.82 | KMO (0.50) | THRBTDP1KMT2ARAB9ATSHR | |
| SCHEMBL14822539 | 0.82 | MAPT (0.70) | THRBTDP1KMT2ARAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432420-B1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7300928-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7291611-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7273857-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-11-16 | — | — | US | disclosed |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-14 | — | — | US | disclosed |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-07 | — | — | US | disclosed |
| US-7087593-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-02-02 | — | — | US | disclosed |
| EP-1432420-A4 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6951849-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2005-10-04 | — | — | US | disclosed |
| WO-2004089942-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1432420-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | Acadia Pharmaceuticals Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003028650-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | THRB 203/4885TDP1 1801/4885KMT2A 1817/4885 |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | THRB 231/4885TDP1 1845/4885KMT2A 1216/4885 |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | THRB 203/4885TDP1 1801/4885KMT2A 1817/4885 |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | THRB 203/4885TDP1 1801/4885KMT2A 1817/4885 |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | THRB 203/4885TDP1 1801/4885KMT2A 1817/4885 |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | THRB 203/4885TDP1 1801/4885KMT2A 1817/4885 |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | THRB 231/4885TDP1 1845/4885KMT2A 1216/4885 |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | THRB 203/4885TDP1 1801/4885KMT2A 1817/4885 |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | THRB 203/4885TDP1 1801/4885KMT2A 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.